Moderna, Inc. Common Stock (MRNA) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which w...
Moderna, Inc. Common Stock (MRNA) currently trades at a P/S ratio of 24.34 (range: 2.29–30.96, 99th percentile — expensive relative to its history).
Moderna, Inc. Common Stock appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 24.34 | 2.29 | 4.31 | 30.96 | 99th | expensive relative to its history |